-
Neuropsychiatric Disease and Treatment
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
The role of asenapine in the treatment of manic or mixed states associated with bipolar I disorder
Perspectives
(1435) Views (431) Full article downloads
Authors: Pompili M, Venturini P, Innamorati M , Serafini G, Telesforo L, Lester D, Tatarelli R, Girardi P
Published Date May 2011
Volume 2011:7(1) Pages 259 - 265
DOI: http://dx.doi.org/10.2147/NDT.S17259
Maurizio Pompili1,2, Paola Venturini1, Marco Innamorati1, Gianluca Serafini1, Ludovica Telesforo1, David Lester3, Roberto Tatarelli1, Paolo Girardi11Department of Neurosciences, Mental Health and Sensory Functions, Suicide Prevention Center, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy; 2McLean Hospital, Harvard Medical School, Boston, MA, USA; 3The Richard Stockton College of New Jersey, Pomona, NJ, USA
Background: Bipolar disorders (BD) are of particular public health significance as they are prevalent, severe and disabling, and often associated with elevated risks of premature mortality. The aim of this concise overview is to investigate the role of asenapine in the treatment of manic and mixed states associated with BD type 1 disorder.
Method: MedLine, Excerpta Medica and PsycINFO searches were performed to identify papers in English published over the past 7 years. Search terms were "asenapine", "manic" OR "mixed states", "bipolar I disorder". Subjects included in this study suffered from BD type 1 disorder.
Results: To date, only four studies of asenapine for the treatment of manic or mixed episodes associated with BD type 1 have been published.
Conclusion: Research indicates that asenapine is generally well-tolerated, and that asenapine is efficacious and not inferior to olanzapine in the treatment of mixed or manic episodes associated with BD type 1 in the short-term and long-term.
Keywords: asenapine, bipolar disorder, side effects
Other articles by Professor Maurizio Pompili
Persistent suicide risk in clinically improved schizophrenia patients: challenge of the suicidal dimension
Psychiatric comorbidity and suicide risk in patients with chronic migraine
Suicide risk in depression and bipolar disorder: Do impulsiveness-aggressiveness and pharmacotherapy predict suicidal intent?
Readers of this article also read:
Herpes zoster in the T1 dermatome presenting with Horner’s syndrome, radicular weakness, and postherpetic neuralgia
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder
An ultra-high input impedance ECG amplifier for long-term monitoring of athletes
Editorial
Role of sublingual asenapine in treatment of schizophrenia
Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder
Helicobacter pylori infection and primary open-angle glaucoma: is there a connection?
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- Journal Indexing
See where all the Dove Press journals are indexed
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor
- Implementing the 2009 Institute of Medicine recommendations on resident physician work hours, supervision, and safety
- Moderate alcohol consumption and cognitive risk
- Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference




